Inactive Instrument

Highlights Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	Mar. 13	MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	Jan. 31	CI
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04	CI
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	Dec. 27	CI
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages	Nov. 28	CI
Kuros Biosciences Books Greater Loss; Revenue Grows	23-08-09	MT
Kuros Biosciences AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-29	CI
Kuros Biosciences Net Loss Widens in FY22	23-03-15	MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones	22-08-23	CI
Kuros Biosciences Widens Net Loss in H1; Revenue Jumps	22-08-09	MT
Kuros Biosciences AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	22-06-02	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	22-06-02	MT
Switzerland's Kuros Biosciences Launches Bone Graft MagnetOs In US	22-05-18	MT
Kuros Biosciences’S Magnetos Flex Matrix Receives Clearance by U.S. Food and Drug Administration for Spinal Indications	22-04-21	CI
Kuros Biosciences' Net Loss Shrinks in FY21 as Revenue Soars	22-03-16	MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Highlights

Filters